These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9172588)

  • 1. [Pathophysiological significance of natriuretic peptide receptor].
    Naruse M; Naruse K; Yoshimoto T; Tanabe A; Demura H
    Nihon Rinsho; 1997 Apr; 55 Suppl 2():549-52. PubMed ID: 9172588
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular significance of the natriuretic peptide receptor, guanylyl cyclase-A, from studies using genetically engineered mice].
    Kishimoto I
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():38-42. PubMed ID: 15506333
    [No Abstract]   [Full Text] [Related]  

  • 3. Natriuretic hormones.
    Espiner EA; Richards AM; Yandle TG; Nicholls MG
    Endocrinol Metab Clin North Am; 1995 Sep; 24(3):481-509. PubMed ID: 8575406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism between the vascular renin-angiotensin and natriuretic peptide systems in vascular remodelling.
    Itoh H; Nakao K
    Blood Press Suppl; 1994; 5():49-53. PubMed ID: 7534179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Natriuretic peptide system].
    Itoh H; Nakao K
    Nihon Rinsho; 1997 Aug; 55(8):1923-36. PubMed ID: 9284403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-type natriuretic peptide and guanylyl cyclase B receptor.
    Schulz S
    Peptides; 2005 Jun; 26(6):1024-34. PubMed ID: 15911070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations.
    Hirose M; Furukawa Y; Kurogouchi F; Nakajima K; Miyashita Y; Chiba S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):70-6. PubMed ID: 9655843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Natriuretic peptides and essential arterial hypertension].
    Lucarelli K; Iacoviello M; Dessì-Fulgheri P; Sarzani R; Romito R; Sorrentino S; Forleo C; Rizzon B; De Tommasi E; Rappelli A; Rizzon P; Pitzalis MV
    Ital Heart J Suppl; 2002 Nov; 3(11):1085-91. PubMed ID: 12506509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A.
    Kuhn M
    Circ Res; 2003 Oct; 93(8):700-9. PubMed ID: 14563709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of natriuretic peptide receptor C.
    Hamilton EJ; Figtree GA; Rasmussen HH
    Circ Res; 2011 Feb; 108(4):e4; author reply e5. PubMed ID: 21335426
    [No Abstract]   [Full Text] [Related]  

  • 11. Atrial natriuretic peptide-C receptor-induced attenuation of adenylyl cyclase signaling activates phosphatidylinositol turnover in A10 vascular smooth muscle cells.
    Mouawad R; Li Y; Anand-Srivastava MB
    Mol Pharmacol; 2004 Apr; 65(4):917-24. PubMed ID: 15044621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy.
    Kishimoto I; Rossi K; Garbers DL
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2703-6. PubMed ID: 11226303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of functional type B natriuretic peptide receptor in human ocular cells.
    Pang IH; Shade DL; Matsumoto S; Steely HT; DeSantis L
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1724-31. PubMed ID: 8759339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical development of drugs related to natriuretic peptides].
    Furuya M
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():170-5. PubMed ID: 15506363
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current status and future prospects of C-type natriuretic peptide].
    Park K; Itoh H; Nakao K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():151-6. PubMed ID: 15506360
    [No Abstract]   [Full Text] [Related]  

  • 16. Depletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux.
    Trachte GJ
    J Pharmacol Exp Ther; 2000 Jul; 294(1):210-5. PubMed ID: 10871314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP-regulated module (ARM) of the atrial natriuretic factor receptor guanylate cyclase.
    Duda T; Venkataraman V; Ravichandran S; Sharma RK
    Peptides; 2005 Jun; 26(6):969-84. PubMed ID: 15911066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence and biological activity of C-type natriuretic peptide-dependent guanylate cyclase-coupled receptor in the penile corpus cavernosum.
    Kim SZ; Kim SH; Park JK; Koh GY; Cho KW
    J Urol; 1998 May; 159(5):1741-6. PubMed ID: 9554404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric regulatory step and configuration of the ATP-binding pocket in atrial natriuretic factor receptor guanylate cyclase transduction mechanism.
    Sharma RK; Yadav P; Duda T
    Can J Physiol Pharmacol; 2001 Aug; 79(8):682-91. PubMed ID: 11558677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine and paracrine actions of natriuretic peptides in the heart.
    D'Souza SP; Davis M; Baxter GF
    Pharmacol Ther; 2004 Feb; 101(2):113-29. PubMed ID: 14761702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.